109 related articles for article (PubMed ID: 14700225)
1. Tracking the distribution of "ecstasy" tablets by Raman composition profiling: a large scale feasibility study.
Bell SE; Barrett LJ; Burns DT; Dennis AC; Speers SJ
Analyst; 2003 Nov; 128(11):1331-5. PubMed ID: 14700225
[TBL] [Abstract][Full Text] [Related]
2. Composition profiling of seized ecstasy tablets by Raman spectroscopy.
Bell SE; Burns DT; Dennis AC; Matchett LJ; Speers JS
Analyst; 2000 Oct; 125(10):1811-5. PubMed ID: 11070550
[TBL] [Abstract][Full Text] [Related]
3. Rapid analysis of ecstasy and related phenethylamines in seized tablets by Raman spectroscopy.
Bell SE; Burns DT; Dennis AC; Speers JS
Analyst; 2000 Mar; 125(3):541-4. PubMed ID: 10829348
[TBL] [Abstract][Full Text] [Related]
4. The profiling of MDMA tablets: a study of the combination of physical characteristics and organic impurities as sources of information.
Milliet Q; Weyermann C; Esseiva P
Forensic Sci Int; 2009 May; 187(1-3):58-65. PubMed ID: 19345026
[TBL] [Abstract][Full Text] [Related]
5. Screening tablets for DOB using surface-enhanced Raman spectroscopy.
Bell SE; Fido LA; Sirimuthu NM; Speers SJ; Peters KL; Cosbey SH
J Forensic Sci; 2007 Sep; 52(5):1063-7. PubMed ID: 17680788
[TBL] [Abstract][Full Text] [Related]
6. Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK.
Wood DM; Stribley V; Dargan PI; Davies S; Holt DW; Ramsey J
Emerg Med J; 2011 Sep; 28(9):764-5. PubMed ID: 20724467
[TBL] [Abstract][Full Text] [Related]
7. Chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in Hong Kong.
Cheng WC; Poon NL; Chan MF
J Forensic Sci; 2003 Nov; 48(6):1249-59. PubMed ID: 14640267
[TBL] [Abstract][Full Text] [Related]
8. Isotopic characterisation of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethylamphetamine (ecstasy).
Carter JF; Titterton aE; Murray M; Sleeman R
Analyst; 2002 Jun; 127(6):830-3. PubMed ID: 12146919
[TBL] [Abstract][Full Text] [Related]
9. Combining attenuated total reflectance- infrared spectroscopy and chemometrics for the identification and the dosage estimation of MDMA tablets.
Deconinck E; Van Campenhout R; Aouadi C; Canfyn M; Bothy JL; Gremeaux L; Blanckaert P; Courselle P
Talanta; 2019 Apr; 195():142-151. PubMed ID: 30625524
[TBL] [Abstract][Full Text] [Related]
10. The variability of ecstasy tablets composition in Brazil.
Togni LR; Lanaro R; Resende RR; Costa JL
J Forensic Sci; 2015 Jan; 60(1):147-51. PubMed ID: 25125149
[TBL] [Abstract][Full Text] [Related]
11. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department.
Sherlock K; Wolff K; Hay AW; Conner M
J Accid Emerg Med; 1999 May; 16(3):194-7. PubMed ID: 10353046
[TBL] [Abstract][Full Text] [Related]
12. 15N isotopic analyses: a powerful tool to establish links between seized 3,4-methylenedioxymethamphetamine (MDMA) tablets.
Palhol F; Lamoureux C; Naulet N
Anal Bioanal Chem; 2003 Jun; 376(4):486-90. PubMed ID: 12819848
[TBL] [Abstract][Full Text] [Related]
13. Solid-phase extraction for profiling of ecstasy tablets.
Rashed AM; Anderson RA; King LA
J Forensic Sci; 2000 Mar; 45(2):413-7. PubMed ID: 10782963
[TBL] [Abstract][Full Text] [Related]
14. Development of a Library Search-Based Screening System for 3,4-Methylenedioxymethamphetamine in Ecstasy Tablets Using a Portable Near-Infrared Spectrometer.
Tsujikawa K; Yamamuro T; Kuwayama K; Kanamori T; Iwata YT; Miyamoto K; Kasuya F; Inoue H
J Forensic Sci; 2016 Sep; 61(5):1208-14. PubMed ID: 27362667
[TBL] [Abstract][Full Text] [Related]
15. Development and application of a high-performance liquid chromatography method using monolithic columns for the analysis of ecstasy tablets.
Mc Fadden K; Gillespie J; Carney B; O'Driscoll D
J Chromatogr A; 2006 Jul; 1120(1-2):54-60. PubMed ID: 16466734
[TBL] [Abstract][Full Text] [Related]
16. [Ecstasy--the status in French-speaking Switzerland. Composition of seized drugs, analysis of biological specimens and short review of its pharmacological action and toxicity].
Giroud C; Augsburger M; Sadeghipour F; Varesio E; Veuthey JL; Rivier L
Praxis (Bern 1994); 1997 Mar; 86(13):510-23. PubMed ID: 9157497
[TBL] [Abstract][Full Text] [Related]
17. Content of ecstasy in the Netherlands: 1993-2008.
Vogels N; Brunt TM; Rigter S; van Dijk P; Vervaeke H; Niesink RJ
Addiction; 2009 Dec; 104(12):2057-66. PubMed ID: 19804461
[TBL] [Abstract][Full Text] [Related]
18. Crystals and tablets in the Spanish ecstasy market 2000-2014: Are they the same or different in terms of purity and adulteration?
Vidal Giné C; Ventura Vilamala M; Fornís Espinosa I; Gil Lladanosa C; Calzada Álvarez N; Fitó Fruitós A; Rodríguez Rodríguez J; Domíngo Salvany A; de la Torre Fornell R
Forensic Sci Int; 2016 Jun; 263():164-168. PubMed ID: 27129144
[TBL] [Abstract][Full Text] [Related]
19. Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004.
Giraudon I; Bello PY
Subst Use Misuse; 2007; 42(10):1567-78. PubMed ID: 17918027
[TBL] [Abstract][Full Text] [Related]
20. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.
Parrott AC
Psychopharmacology (Berl); 2004 May; 173(3-4):234-41. PubMed ID: 15007594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]